| Order book | Intl contracted revenue AUD 232mn; Noumed AUD 202mn |
|---|---|
| Demand visibility | >50% consolidated revenue contracted long-term |
Growth
FY23-FY26 CAGR: branded generics 15.6%, CDMO 355.6% (as stated). Export share rose from 3% to 63% of revenue.
Outlook
Adelaide ops Jan 2027; Saicriti facility Jul 2027; EU accreditation within 12 months of completion; EU revenue from FY29. Rs 571cr capex programme.
Risks
No EU injectable accreditation today. Unit II at 97% utilisation. Jeedimetla units discontinued, facility delayed about four months. Noumed margin is distribution-only (~10%).
Last quarter's promises, checked
Partly delivered
- Adelaide physical completion Jan 2027 → deck still says Jan 2027, not yet due (= PARTIAL)
Missed
- Saicriti completion Apr 2027 → Jul 2027 (= MISS)
- Units I-II Rs83.83cr upgrade → Units I-II discontinued, funds moved to Saicriti (= MISS)
- EU-GMP plant at Apr 2027 completion → EU accreditation 12m post-completion, EU revenue FY29 (= MISS)
Investor Presentation filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹521.95
- Market cap
- ₹2,306 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 111.0×Sector 45.9×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Results Update
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
Sai Parenterals Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 66.7% YoY
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +66.7% YoY
Sai Parenterals Board Meeting Date
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.
Sai Parenterals Acquisition Worth ₹15 Cr
Sai Parenterals Limited has acquired a 60% stake in Prathyak Laboratories Private Limited for ₹15 Crore. This acquisition provides an operational R&D facility in Hyderabad.
- Value
- ₹15.00 Cr
- product pipeline
- 150.0 SKUs
Sai Parenterals Other Announcement
Sai Parenterals Ltd submitted the Monitoring Agency Report for the quarter ended 30th June 2026 regarding the utilization of IPO proceeds, as per SEBI regulations.